These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 19318950)

  • 21. The finasteride prostate cancer prevention trial (PCPT)--what have we learned?
    Mellon JK
    Eur J Cancer; 2005 Sep; 41(13):2016-22. PubMed ID: 16061372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-grade prostate cancer and the prostate cancer prevention trial.
    Logothetis CJ; Schellhammer PF
    Cancer Prev Res (Phila); 2008 Aug; 1(3):151-2. PubMed ID: 19138948
    [No Abstract]   [Full Text] [Related]  

  • 23. [The PCPT trial].
    Hamdy FC; Rouprêt M
    Prog Urol; 2008 Apr; 18 Suppl 3():S40-3. PubMed ID: 18455082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Finasteride for prevention of prostate cancer.
    Med Lett Drugs Ther; 2008 Jun; 50(1289):49-50. PubMed ID: 18583946
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386.
    Festuccia C; Gravina GL; Muzi P; Pomante R; Angelucci A; Vicentini C; Bologna M
    J Urol; 2008 Jul; 180(1):367-72. PubMed ID: 18499161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Update on chemoprevention for prostate cancer.
    Strope SA; Andriole GL
    Curr Opin Urol; 2010 May; 20(3):194-7. PubMed ID: 20216317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevention of prostate cancer with finasteride.
    Burke HB
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562806
    [No Abstract]   [Full Text] [Related]  

  • 29. The influence of prostate volume on prostate-specific antigen performance: implications for the prostate cancer prevention trial outcomes.
    Elliott CS; Shinghal R; Presti JC
    Clin Cancer Res; 2009 Jul; 15(14):4694-9. PubMed ID: 19584168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer.
    Orvieto M; Eggener S
    Eur Urol; 2009 May; 55(5):1073-4. PubMed ID: 19200640
    [No Abstract]   [Full Text] [Related]  

  • 31. Prostate cancer: a serious disease suitable for prevention.
    Fitzpatrick JM; Schulman C; Zlotta AR; Schröder FH
    BJU Int; 2009 Apr; 103(7):864-70. PubMed ID: 19302133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
    Thompson IM; Chi C; Ankerst DP; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Natl Cancer Inst; 2006 Aug; 98(16):1128-33. PubMed ID: 16912265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Finasteride (Propecia) and the promotion of high-grade prostate cancer.
    Pitts WR
    Arch Dermatol; 2004 Jul; 140(7):885-6. PubMed ID: 15262708
    [No Abstract]   [Full Text] [Related]  

  • 34. Estimated impact of the Prostate Cancer Prevention Trial on population mortality.
    Unger JM; Thompson IM; LeBlanc M; Crowley JJ; Goodman PJ; Ford LG; Coltman CA
    Cancer; 2005 Apr; 103(7):1375-80. PubMed ID: 15739207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Practical follow-up of a patient treated with finasteride in screening for prostate cancer].
    Villers A
    Prog Urol; 2008 Apr; 18 Suppl 3():S58-62. PubMed ID: 18455086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].
    Djavan B; McConnell J
    Wien Med Wochenschr; 1996; 146(8):165-8. PubMed ID: 8767401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
    Lotan Y; Cadeddu JA; Lee JJ; Roehrborn CG; Lippman SM
    J Clin Oncol; 2005 Mar; 23(9):1911-20. PubMed ID: 15774783
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention of prostate cancer with finasteride.
    Rubin MA; Kantoff PW
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14561801
    [No Abstract]   [Full Text] [Related]  

  • 40. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
    Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Parnes HL; Lippman SM; Coltman CA
    J Urol; 2007 May; 177(5):1749-52. PubMed ID: 17437804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.